Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 14/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800656 | 0.87 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL2858767 | 0.87 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL2858768 | 0.87 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL2858162 | 0.87 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL2785002 | 0.87 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL702650 | 0.84 | TACR1 (0.45) | TACR1NPC1MTORRAB9A | |
| SCHEMBL7042420 | 0.82 | CHRNA7 (0.53) | CHRNA7TACR1 | |
| SCHEMBL7046951 | 0.80 | CHRNA7 (0.51) | CHRNA7TACR1 | |
| SCHEMBL8800779 | 0.76 | TACR1 (0.51) | TACR1 | |
| SCHEMBL9323045 | 0.74 | TACR1 (0.49) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8143272-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8124618-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124619-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124620-B2 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8084462-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110071189-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071188-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | ATTENUA, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6953855-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1053236-A1 | PYRDIYL-BRIIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000034276-A1 | PYRIDYL-BRIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | CHRNA7 11/4885TACR1 105/4885SMN1; SMN2 2009/4885 |
| US-20110071189-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885TACR1 197/4885SMN1; SMN2 3222/4885 |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | CHRM1, CHRNA7, CHRM3 | CHRNA7 2/4885TACR1 102/4885SMN1; SMN2 1217/4885 |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNA3 | CHRNA7 1/4885TACR1 358/4885SMN1; SMN2 3105/4885 |
| US-20110071188-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885TACR1 84/4885SMN1; SMN2 3238/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | CHRNA7 1/4885TACR1 229/4885SMN1; SMN2 3112/4885 |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885TACR1 197/4885SMN1; SMN2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.